Lunai Bioworks

What Lunai Bioworks does

Lunai Bioworks is a publicly traded AI-driven phenomics platform company (NASDAQ: LNAI, formerly Renovaro Inc.) headquartered in Sacramento, California, that integrates multimodal biological data, machine learning, and in vivo validation using CRISPR-modified zebrafish models to discover therapeutics in oncology, neurology, and biodefense. Its core technology stack comprises the Augusta AI/ML engine, the Elion machine-learning engine, and the Phenograph translational knowledge graph, complemented by proprietary computer vision that tracks behavioral, morphological, and physiological responses in living zebrafish at hundreds to thousands of compounds screened per week. BioSymetrics Inc., a wholly owned subsidiary acquired via merger in April 2025, anchors the AI platform layer and provides pre-existing partnerships with Janssen (J&J), Pfizer, Merck, Supernus Pharma, and Deerfield Cures. The company's recent acquisition activity — a $20 million purchase of blood-brain barrier prodrug technology from Clemann Group, SAS in March 2026 and a $12.5 million acquisition of nose-to-brain drug delivery IP from Oncotelic Therapeutics in May 2026 — extended the platform from discovery into CNS therapeutic assets targeting Alzheimer's and biodefense applications.

The company serves three primary customer segments: (1) major pharmaceutical companies seeking AI-driven drug discovery, biomarker discovery, and patient stratification partnerships; (2) U.S. government agencies including BARDA, DoD, DHS, and DARPA for chemical and biological countermeasure development under programs ranging $400 million to $1.2 billion each; and (3) academic medical centers and foundations for translational research collaborations, exemplified by partnerships with Amsterdam University Medical Center, BrainStorm Therapeutics, Geneial, Leiden University Medical Center, and the University of Florida. Revenue mechanics rest on a mix of strategic platform partnerships and licensing, government contracts and grants, and direct pharma co-development structures. The company secured a competitive NIH STTR grant in January 2026 and announced its first revenue-generating multi-year commercial defense collaboration through BioSymetrics in April 2026 for AI-enabled chemical threat assessment, while pursuing the larger Pathfinder Consortium academic-industry alliance launched in March 2026.

Operational and financial conditions remain stressed. The company recorded negative earnings per share of -$7.55 and zero disclosed revenue across multiple reporting periods, with employee furloughs enacted in February 2026 and voluntary CEO and CFO salary deferrals. Two reverse stock splits (10:1 in September 2025 and 1:8 in May 2026) were required to maintain Nasdaq minimum bid price compliance, and the market capitalization collapsed from above $350 million to under $30 million over the prior year. Litigation is ongoing in U.S. District Court for the District of Delaware regarding alleged naked short selling, with court records showing 29.6 million shares (81.6% of outstanding) failing to deliver.

Name

Lunai Bioworks

Legal name

Lunai Bioworks Inc.

Website

https://lunaibioworks.com

Company type

Public

Operating status

Operating

Headcount range

1–10 employees

Short description

Lunai Bioworks is a publicly traded AI phenomics platform (NASDAQ: LNAI) integrating multimodal biological data and zebrafish in vivo validation to discover therapeutics in oncology, neurology, and biodefense for pharmaceutical companies, U.S. government agencies, and academic research centers.

Ownership category

akta.pro rank

Product category

AI-driven drug discovery and phenomics platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

Keywords

• AI drug discovery
• Phenomics platform
• Biodefense therapeutics
• Precision neurology
• Zebrafish phenotypic screening

Headquarters

HQ city

Sacramento

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Defense and Biodefense Contracts: Revenue-generating multi-year commercial defense collaboration through BioSymetrics for AI-enabled chemical threat assessment. The company targets federal procurement programs ranging from $400 million to $1.2 billion per program through BARDA, DoD, and Homeland Security.
2. Pharmaceutical Platform Partnerships: Revenue through strategic partnerships with pharmaceutical companies for platform access, drug discovery collaborations, biomarker programs, and licensing deals. The company intends to generate development-ready neurology programs designed for pharmaceutical partnering, licensing, and downstream co-development structures.
3. NIH and Non-Dilutive Funding: Competitive STTR grant from NIH supporting translational pipeline and platform expansion. Company pursues non-dilutive funding opportunities from government agencies for biodefense and rare disease programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Lunai Bioworks is an AI-driven phenomics platform company that integrates multimodal biological data with machine learning and validates predictions in living systems using CRISPR-modified zebrafish models and computer vision. The company delivers therapeutic discovery, biomarker identification, and patient stratification services to pharmaceutical companies, and provides AI-enabled chemical threat assessment capabilities to U.S. government biodefense agencies. It also develops and has acquired blood-brain barrier and nose-to-brain drug delivery technologies targeting CNS disorders and biodefense applications.

Product overview

Lunai Bioworks is a phenomics-driven drug discovery company integrating real-world disease signals with machine learning and experimental validation. The platform architecture consists of multiple interconnected components: Augusta serves as the core AI/ML engine for precision drug discovery; Elion provides the AI-driven biomarker identification and analytics capability; Phenograph acts as the translational engine mapping clinical signals to therapeutic targets; In Vivo Modeling with Machine Vision delivers zebrafish-based phenotypic screening and validation. BioSymetrics operates as the wholly owned subsidiary driving AI-powered drug discovery. The company acquired the N2B (nose-to-brain) and BBB (blood-brain barrier) delivery platforms to address CNS drug delivery challenges. The Transformer Platform embeds neurotoxicity intelligence for biodefense applications. Programs span oncology (dendritic cell immunotherapy), neurology (epilepsy, Parkinson's, alcohol use disorder via KCC2), and biodefense (chemical threat assessment via Pathfinder Consortium).

Differentiator

Problem solved

Functional benefit

Brands

• Augusta: AI-powered Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and validation. Built on Renovaro Cube and Elion platforms, focused on neurology.
• Elion
• Phenograph
• Pathfinder Consortium

Products and services

• Augusta Platform AI/ML engine integrating genomic, proteomic, and phenotypic data into a unified disease view for precision drug discovery and biomarker identification; forms the core computational foundation for Lunai's neurology programs and is offered to pharmaceutical partners for collaborative R&D.
• Elion Platform AI and machine learning engine that uncovers complex biological relationships to accelerate discovery of diagnostics and therapeutics, processing large-scale biological and clinical data for drug development applications through the BioSymetrics subsidiary.
• Phenograph Platform Translational engine that maps human clinical signals to prioritized therapeutic targets, enabling patient stratification and drug repurposing by linking patient phenotypes to model system phenotypes for validation.
• In Vivo Modeling with Machine Vision Service High-throughput zebrafish phenotypic screening service combined with proprietary AI computer vision to track behavior, morphology, and physiology in real time, exposing efficacy and safety signals that static models cannot reveal.
• Transformer-Based Neurotoxicity Intelligence Platform Transformer-based platform embedding biological risk intelligence into LLM pipelines, using virtual chemical screening to identify potentially toxic compounds early and accelerate therapeutic discovery while providing dual-use safeguards for biodefense.
• Blood-Brain Barrier (BBB) Delivery Platform BBB-crossing prodrug delivery technology enabling therapeutics to cross the blood-brain barrier, remain inactive systemically, and activate specifically in the brain; acquired from Clemann Group for CNS Alzheimer's therapies and broader neurological applications.
• N2B (Nose-to-Brain) Drug Delivery System Nose-to-brain drug delivery system IP portfolio designed to bypass the blood-brain barrier for CNS drug delivery; acquired from Oncotelic Therapeutics for biodefense and Alzheimer's disease applications.

Quantifiable outcome

• AChE inhibitor differentiation accuracy of 0.94 AUROC
• +2 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered major, strategic, core and minor.

• BrainStorm TherapeuticsmajorStrategic or Co-development Partner · 28 May 2026Strategic collaboration to jointly discover and advance novel therapeutic targets for neurological diseases including Parkinson's disease and rare genetic epilepsies, supported by a LouLou Foundation grant. Combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation with BrainStorm's proprietary human-derived organoid systems.
• Amsterdam University Medical CenterstrategicStrategic or Co-development Partner · 13 May 2026Exclusive collaboration agreement to jointly evaluate and develop blood platelet RNA diagnostics. Four-year initial term with joint intellectual property management and plans to establish dedicated company in Netherlands for commercialization.
• Oncotelic TherapeuticsstrategicTechnology or Integration · 6 May 2026Acquisition of worldwide rights to N2B (nose-to-brain) drug delivery system IP portfolio for biodefense and Alzheimer's disease applications in exchange for $12.5 million in Lunai Series B Convertible Preferred Stock. Oncotelic maintains rights outside specified fields including Parkinson's and sexual dysfunction.
• GeneialstrategicStrategic or Co-development Partner · 15 April 2026Non-binding Letter of Intent with Geneial to build trial-ready patient cohorts for rare neurological disorders, converting fragmented patient-generated data into structured datasets for drug development and clinical trial recruitment.
• Pathfinder Consortium (Harvard, Brigham and Women's Hospital, University of Utah, Purdue, University of Colorado)coreStrategic or Co-development Partner · 19 March 2026National academic-industry alliance through BioSymetrics designed to consolidate U.S. chemical warfare preparedness resources into unified infrastructure for accelerating medical countermeasure development from traditional 10-year timelines to approximately 3 years.
• Leiden University Medical CenterstrategicStrategic or Co-development Partner · 16 October 2025Multi-institutional research collaboration for Duchenne muscular dystrophy biomarker discovery. Analyzed over 700 longitudinal serum samples using SomaScan proteomics platform, identifying prognostic biomarkers published in Nature Communications.
• University of FloridastrategicStrategic or Co-development Partner · 16 October 2025Research collaboration for Duchenne muscular dystrophy biomarker discovery alongside Leiden University Medical Center and BioSymetrics, contributing clinical expertise and patient samples.
• American Defense InternationalstrategicGTM or Marketing Partner · 4 September 2025Retained Washington D.C.-based government affairs firm to position Lunai's AI-enabled biomedical data platforms for U.S. government agencies including DoD, BARDA, and DARPA for chemical and biological weapons countermeasure development.
• BioSymetricscoreStrategic or Co-development Partner · 8 April 2025BioSymetrics is a wholly owned subsidiary of Lunai Bioworks following merger completion in April 2025. Provides proprietary AI-driven drug discovery platform including Elion and Phenograph systems, zebrafish-based phenotypic screening, and partnerships with Janssen, Pfizer, Merck, and Supernus Pharma.
• Dante LabsminorStrategic or Co-development Partner · 1 December 2022Partner collaboration on genetic epilepsies presented at American Epilepsy Society meeting. BioSymetrics analyzed genetic data from patients with different epilepsy phenotypes and identified novel gene-disease relationships for patient phenoclusters.

Scale indicators8 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Exscientia: Exscientia is an AI-driven pharmatech company that pioneered automated drug design and has major pharma partnerships. Direct peer in enterprise pharma platform deals and AI-driven small-molecule discovery.
• Atomwise: Atomwise applies deep learning to structure-based small-molecule discovery with pharma collaborations. Closely comparable AI-first platform targeting similar pharma partnership pipeline.
• Schrödinger, Inc. Schrödinger operates a physics-based computational platform for drug discovery serving major pharmaceutical companies. Comparable as an AI/ML discovery platform partner to large pharma with similar enterprise GTM.
• Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable to Lunai in combining AI prediction with in vivo/phenotypic validation, and competing for similar pharma platform partnerships.
• Insitro: Insitro combines ML with high-throughput biology and disease models for drug discovery. Comparable in pairing AI with experimental validation systems, competing for similar pharma co-development deals.
• Owkin: Owkin applies AI to patient-derived data and multi-omics analysis for drug discovery and diagnostics. Comparable multimodal data + ML approach serving biopharma partnerships.

Broad incumbents

• Isomorphic Labs: Isomorphic Labs (Alphabet-owned) leverages AlphaFold-based computational biology for drug discovery partnerships with Novartis and Eli Lilly. Broader incumbent with deeper resources and pharma partnerships.
• AbCellera Biologics: AbCellera is an AI-enabled antibody discovery platform with extensive pharma partnerships. Adjacent peer in the AI-driven biologics/discovery space but focused on antibodies rather than small molecules/phenomics.

Emerging players

• Lantern Pharma: Lantern Pharma uses AI and genomic data to identify responders and repurpose oncology compounds. Comparable as smaller-cap AI-oncology player but narrower therapeutic focus than Lunai.
• Xaira Therapeutics: Xaira Therapeutics applies foundation models to drug discovery and was founded by DeepMind architects. Emerging AI-discovery player with comparable ML-first approach, though much better capitalized.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/lunaibioworks
• LinkedInlinkedin.com/company/lunai-bioworks

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lunai Bioworks